1-5 of 5
Peter Johnson, MDFRCP
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody ® -CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Pieternella Lugtenburg, MD PhD, Rogier Mous, MD PhD, Michael Roost Clausen, Martine E.D. Chamuleau, Peter Johnson, MDFRCP, Kim Linton, PhD, Simon Rule, Roberto S Oliveri, MD PhD, Dena DeMarco, Ida H Hiemstra, PhD, Guang Chen, Ada Azaryan, Manish Gupta, Tahamtan Ahmadi, Martin Hutchings, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 758.
https://doi.org/10.1182/blood-2019-121460
Published: 2019
Journal Articles

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Radhakrishnan Ramchandren, MD, Peter Johnson, MDFRCP, Nilanjan Ghosh, MD PhD, Jia Ruan, MD PhD, Kirit M. Ardeshna, MA, MD FRCP, FRCPath, Roderick Johnson, MD, Gregor Verhoef, MD PhD, David Cunningham, MD FRCP, FMedSci, Sven de Vos, MD PhD, Shireen Kassam, MD, Luis Fayad, MD, John Radford, Sarah Bailly, MD, Fritz Offner, MD, David Morgan, MD, Javier Munoz, MD, Jerry Ping, PhD, Kevin Kwei, PhD, Karl Eckert, BA, Jutta K. Neuenburg, MD PhD, Andre Goy, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 761.
https://doi.org/10.1182/blood-2019-121521
Published: 2019
Journal Articles

High Surface IgM Levels Associate with Shorter Response Duration and Bypass of the BTK Blockade during Ibrutinib Therapy in CLL Patients

Giorgia Chiodin, David Dutton, MD, Enrica Antonia Martino, MD, Samantha Drennan, PhD, Ian Tracy, PhD, Laura Ondrisova, Isla Henderson, Annalisa D'Avola, PhD, Christina Pitsillidou, Marek Mraz, MD, Peter Johnson, MDFRCP, Andrew Duncombe, MD, Graham Packham, PhD, Andrew J Steele, PhD, Helen Parker, PhD, Silvia Bonfiglio, Lydia Scarfo, MD, Lesley-Ann Sutton, Paolo Ghia, MD PhD, Matthew John Jerome Rose-Zerilli, PhD, Jonathan C Strefford, PhD, Freda K. Stevenson, DPhil, Francesco Forconi, MD DM, PhD FRCPath
Journal: Blood
Blood (2019) 134 (Supplement_1): 1752.
https://doi.org/10.1182/blood-2019-128899
Published: 2019
Journal Articles

Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial

Peter Johnson, MDFRCP, Sriram Balasubramanian, Brendan Hodkinson, Michael Schaffer, Lori Parisi, S. Martin Shreeve, Steven Sun, Jessica Vermeulen, Laurie H Sehn, MD, Louis Staudt, Anas Younes, MD, Wyndham Wilson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 354.
https://doi.org/10.1182/blood-2019-124443
Published: 2019
Journal Articles

Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel

Findlay Bewicke-Copley, PhD MSc, BSc, Koorosh Korfi, PhD BSc, Shamzah Araf, MRCP, MBBS, PhD, Emil Arjun Kumar, BCh,BM, Thomas E C Cummin, MRCP MBBCh BSc, Margaret Ashton-Key, MD, Sharon Barrans, Suzan Van Hoppe, Cathy Burton, Mohamed Elshiekh, Simon Rule, Nicola Crosbie, Andrew James Clear, BSc, Maria Calaminici, MD PhD, David W. Scott, MBChB, PhD, Lisa M. Rimsza, MD, Menon Geetha, Chulin Sha, Michael A Bentley, Ai Nagano, PhD, Andrew Davies, MD PhD, Daniel Painter, BSc, Alexandra Smith, PhD, John G. Gribben, MD DSc, Kikkeri Naresh, David R Westhead, Jessica Okosun, MD PhD, Peter Johnson, MDFRCP, Jun Wang, PhD, Jude Fitzgibbon, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2769.
https://doi.org/10.1182/blood-2019-124352
Published: 2019